Topic: Payment & Reimbursement

  • Fact Checking the NYT Fact Check on the Trump Proposal

  • A $475,000 price tag for a new cancer drug: crazy or meh?

  • The Conflict Between QALYs and Well-Funded Patient Advocacy Groups

  • Remdesivir Less Expensive for “Government Programs”? Not So Fast.

    Remdesivir Less Expensive for “Government Programs”? Not So Fast.

  • Blueprints for Indication-Specific Pricing

    Blueprints for Indication-Specific Pricing

  • Pharmaceutical Products and Their Value

    Pharmaceutical Products and Their Value

  • Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

    Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

  • Abandon Biosimilars as Biologics are Natural Monopolies

  • List Price, Net Price, and the Rebate Caught in the Middle

  • Overview of Original Subscription Model and Features of LA and WA Proposals

    Overview of Original Subscription Model and Features of LA and WA Proposals